| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |